Expertise in
14
conditions

Martin J. Schlumberger

Gustave Roussy
Villejuif, FR 
Expertise in
14
conditions
Gustave Roussy
Villejuif, FR 
OverviewLocationsClinical Research

Overview

Martin Schlumberger practices in Villejuif, France. Mr. Schlumberger is highly rated in 14 conditions, according to our data. His top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Neuroendocrine Tumor, Thyroidectomy, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug
Study Drug: Vandetanib
Study Phase: Phase 3
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: Sunitinib
Study Phase: Phase 2
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Enrollment Status: Completed
Publish Date: August 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer
Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer
Enrollment Status: Completed
Publish Date: November 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

257 Total Publications

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism.
The unique signature of tyrosine kinase inhibitor-induced hypothyroidism.
Journal: The lancet. Diabetes & endocrinology
Published: May 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schlumberger's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile